EurekAlert! Cancer Research - News Releases

News Releases

Updates every hour. Last Updated: 21-Jun-2026 18:15 ET (21-Jun-2026 22:15 GMT/UTC)

New step toward programmable chemistry may help reduce drug side effects

University of California - San Diego
Peer-Reviewed Publication

Drug delivery and diagnostic imaging often lack specificity, but a new “TRACE” method lets specially‑caged compounds stay inert until a target cell’s enzymes quickly remove the cage, potentially allowing for more precise drug delivery and sharper diagnostic imaging.

Journal: Nature Chemical Biology

Research addresses barriers to success for antibody-based therapies for solid head, neck and pancreatic tumors

Vanderbilt University Medical Center
Peer-Reviewed Publication

A recent paper in Nature Biotechnology examines problems and solutions for antibody-based therapies for solid pancreatic cancers and tumors of the head and neck.

Journal: Nature Biotechnology

Deep Visual Multi-Omics: AI-powered 3D mapping reveals intra-tumor heterogeneity of colorectal cancer

Science China Press
Peer-Reviewed Publication

A new study in Science Bulletin presents DVSTP, a deep learning system that integrates pathology images with spatial transcriptomics and proteomics to map intra-tumor heterogeneity. DVSTP predicts molecular profiles from routine pathology slides, making spatial multi-omics more accessible. Whole–tumor 3D reconstruction reveals that SRSF6 drives immune exclusion and is associated with poor clinical outcomes.

Journal: Science Bulletin

Can taking aspirin uncover asymptomatic bladder cancer?

Wiley
Peer-Reviewed Publication

The presence of blood cells in urine is a sign of bladder cancer. Because aspirin blocks platelets from forming harmful blood clots, the medication can cause mild bleeding or worsen existing bleeding in the urinary tract. Results from a study in the Journal of Internal Medicine suggest that this may prompt a clinician to run tests that uncover an asymptomatic bladder tumor.

Journal: Journal of Internal Medicine

Heather Jacene, MD, named president of the Society of Nuclear Medicine and Molecular Imaging

Society of Nuclear Medicine and Molecular Imaging
Business Announcement

Heather Jacene, MD, has been named president of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). Jacene is currently Chief of Molecular Imaging and Theranostics at Beth Israel Deaconess Medical Center, Clinical Director of Nuclear Medicine/PET-CT and Senior Physician at Dana-Farber Cancer Institute, and Associate Professor of Radiology at Harvard Medical School. SNMMI introduced a new slate of officers during its 2026 Annual Meeting, held May 30 - June 2 in Los Angeles.

Meeting: Society of Nuclear Medicine and Molecular Imaging 2026 Annual Meeting

Gary Ulaner, MD, Ph.D., elected president-elect of the Society of Nuclear Medicine and Molecular Imaging

Society of Nuclear Medicine and Molecular Imaging
Business Announcement

Gary Ulaner, MD, PhD, has been named president-elect of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). Ulaner is currently James & Pamela Muzzy Endowed Chair of Molecular Imaging and Therapy at the Hoag Family Cancer Institute and is Professor of Radiology and Translational Genomics at the University of Southern California. SNMMI introduced a new slate of officers during its 2026 Annual Meeting, held May 30 - June 2 in Los Angeles.

Meeting: Society of Nuclear Medicine and Molecular Imaging 2026 Annual Meeting

Jason Lewis, Ph.D., FSNMMI, named vice president-elect of the Society of Nuclear Medicine and Molecular Imaging

Society of Nuclear Medicine and Molecular Imaging
Business Announcement

Jason S. Lewis, PhD, FSNMMI, has been named vice president-elect of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). Lewis is the Emily Tow Chair in Oncology at Memorial Sloan Kettering Cancer Center (MSK) and deputy director of Sloan Kettering Institute in New York. SNMMI introduced its 2026-27 officers at its 2026 Annual Meeting, held May 30-June 2 in Los Angeles.

Meeting: Society of Nuclear Medicine and Molecular Imaging 2026 Annual Meeting

Damon Runyon Cancer Research Foundation names three new Quantitative Biology Fellows

Damon Runyon Cancer Research Foundation
Grant and Award Announcement

Damon Runyon has awarded Quantitative Biology Fellowships to three outstanding young scientists applying computational approaches to persistent biological questions. Their projects will use machine learning, spatialomics, advanced network modeling, and other technologies to better understand breast cancer risk, improve response to immunotherapies, and identify new chromosomal drivers of cancer. Each postdoctoral scientist will receive independent funding ($240,000 total) to train under the joint mentorship of an established computational scientist and a cancer biologist.

New theranostic approach effectively detects and treats neuroendocrine prostate cancer

Society of Nuclear Medicine and Molecular Imaging
Peer-Reviewed Publication

A novel theranostic approach that targets RET -- a newly identified biomarker for neuroendocrine prostate cancer enables high-contrast PET imaging and effective, safe treatment for this highly aggressive malignancy. Because this disease is often poorly visualized with prostate-specific membrane antigen (PSMA)-based imaging, the RET approach offers an important alternative when conventional molecular imaging and PSMA-directed therapies are unsuitable. This research was presented at the Society of Nuclear Medicine and Molecular Imaging 2026 Annual Meeting.

Journal: Journal of Nuclear Medicine
Meeting: Society of Nuclear Medicine and Molecular Imaging 2026 Annual Meeting

AI helps accelerate breast cancer diagnosis for high-risk women

University of California - San Francisco
Peer-Reviewed Publication

Women with abnormal mammograms often have to wait for weeks to find out whether they have breast cancer.

Now, researchers at UC San Francisco and UC Berkeley have found a way to help reduce the wait and the worry by using AI to quickly identify those who are most likely to have the disease. By triaging these patients, the AI-guided workflow takes women with abnormal scans through the diagnostic process — from imaging to evaluation and sometimes even biopsy — in a single day.

15
16
17
18
19